Question explored with the scientific record
Are statins worth taking?
The short version: statins clearly reduce heart attacks and death in people who already have heart disease, but the benefit for healthy people is much smaller and comes with a real risk of new diabetes.
The evidence here is dominated by trials in people who already had a heart attack, stroke, or blocked artery. In those patients, the numbers are striking. One meta-analysis of 14 randomized trials found statins cut all-cause mortality by about 24% (odds ratio 0.76) [21]. Another showed a 46% reduction in heart attack risk in the perioperative setting [3]. For someone who has already had a cardiovascular event, the benefit is large enough that the diabetes risk is a secondary concern.
For primary prevention in healthy people, the picture is different. A 2021 Israeli cohort of nearly 43,000 new statin users without heart disease found that in people over 70, high adherence reduced major cardiovascular events by about 29% and mortality by about 32% [27]. But the absolute numbers matter: in the older group, the event rate was 16.9% over five years, so a 29% relative reduction means about 5 fewer events per 100 people treated. In younger adults, the benefit was smaller and came with a clear increase in new diabetes [27].
The diabetes risk is real and dose-dependent. A meta-analysis of 13 trials with 91,140 patients found a 9% increase in new diabetes (odds ratio 1.09) [39]. High-intensity statins like atorvastatin 80 mg or rosuvastatin 20 mg carry a higher risk than moderate doses [41]. One 2024 study found that in people with very high LDL, statin use was associated with a 2.4-fold increase in diabetes risk [38]. The mechanism involves impaired insulin signaling and reduced coenzyme Q10, which statins deplete [12, 36].
| Population | Outcome | Statin benefit | Diabetes risk |
|---|---|---|---|
| After heart attack (secondary prevention) | All-cause mortality | ~24% relative reduction [21] | Modest increase |
| After acute coronary syndrome (women) | Composite cardiovascular events | 25% relative reduction [48] | Not significant in this subgroup |
| Primary prevention, age ≥70 | MACE + mortality | ~29-32% relative reduction [27] | No significant increase |
| Primary prevention, age <70 | MACE | ~20% relative reduction [27] | Higher diabetes risk |
| Dialysis patients | All-cause mortality | No benefit (RR 0.98) [24] | Not assessed |
The evidence is almost entirely from industry-funded trials. The meta-analyses combine studies funded by the manufacturers of the statins being tested. No long-term trial compares statin users to true untreated controls for 20 years. The most informative comparison, statin versus placebo in healthy people with normal cholesterol, was never run with hard mortality endpoints.
My call: for anyone who has already had a heart attack, stroke, or coronary stent, the evidence for benefit is strong enough that the diabetes risk is worth accepting. For a healthy person without established heart disease, the benefit is small in absolute terms and the diabetes risk is real, especially with high-dose statins. The decision should be based on your actual 10-year risk, not a lab number alone. Confidence: moderate.
Sources used 10
-
Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery: a review
This systematic review and meta-analysis evaluates the impact of perioperative statin therapy on clinical outcomes in statin-naive patients undergoing surgery, finding significant reductions in mortality, myocardial infarction, and atrial fibrillation, particularly in cardiac su…
DOI: 10.1093/bja/aeu295 -
Newly Initiated Statin Treatment Is Associated with Decreased Plasma Coenzyme Q10 Level After Acute ST-Elevation Myocardial Infarction
This study investigates the impact of newly initiated statin treatment on plasma Coenzyme Q10 levels in non-diabetic, statin-naïve patients following acute ST-elevation myocardial infarction, revealing a significant reduction in CoQ10 levels without correlating with myopathy mar…
DOI: 10.3390/ijms26010106 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
Meta-analysis of statin therapy in maintenance dialysis patients
This meta-analysis investigates the effects of statin therapy on major clinical outcomes in maintenance dialysis patients, revealing significant improvements in dyslipidemia and inflammatory markers but no impact on cardiovascular or all-cause mortality.
DOI: 10.3109/0886022x.2015.1061871 -
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
A six-year longitudinal study identifies a statin-independent association between low LDL-cholesterol and risk of type 2 diabetes
A six-year population-based cohort study in Naples, Italy shows an inverse association between LDL-cholesterol levels and incident type 2 diabetes risk that is largely independent of statin use, with the strongest risk at very low LDL-C and a statin-associated increase in risk o…
DOI: 10.1186/s12933-025-02964-6 -
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
This meta-analysis investigates the relationship between statin therapy and the risk of developing diabetes, finding a slight increase in diabetes risk associated with statin use, particularly in older populations, while emphasizing that the cardiovascular benefits of statins ou…
DOI: 10.1016/s0140-6736(09)61965-6 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Benefit of Intensive Statin Therapy in Women
In the PROVE IT-TIMI 22 trial, intensive statin therapy reduced the primary composite cardiovascular endpoint in women after acute coronary syndrome (25% relative risk reduction, P=0.04) with no significant sex interaction.
DOI: 10.1161/circoutcomes.110.957720